Mosanna Therapeutics Pioneers Breakthrough Nasal Spray for Sleep Apnea with $80M Series A Funding
Deal News | Jun 09, 2025 | EQT
EQT Life Sciences has spearheaded an $80 million Series A funding round for Mosanna Therapeutics, a Basel, Switzerland-based clinical-stage biotech company. This investment marks a significant milestone in Mosanna's goal to develop MOS118, a novel nasal spray treatment for obstructive sleep apnea (OSA), which impacts nearly one billion people globally. Unlike traditional treatments that focus on mechanical solutions, Mosanna's approach tackles sleep apnea through the neurological and muscular dysfunction underlying the condition. This funding will advance MOS118 through Phase 2 clinical development and aid in expanding Mosanna's therapeutic pipeline. The firm has also appointed seasoned biotech executive David Weber as CEO, positioning the company for its next stage of growth. This strategic investment supports Mosanna’s transformative solution to improve patient outcomes in a largely untapped market.
Sectors
- Biotechnology
- Healthcare
- Private Equity & Venture Capital
Geography
- Switzerland – Mosanna Therapeutics is headquartered in Basel, Switzerland, where key developments and advancements for the company take place.
- USA – Mosanna Therapeutics also has an office in Redwood City, California, indicating its operations span to the United States.
- Europe – EQT Life Sciences, part of the European venture capital ecosystem, is significantly involved in this Series A funding round.
Industry
- Biotechnology – The article is focused on Mosanna Therapeutics, a biotech company developing a nasal spray treatment for sleep apnea, utilizing advanced biotechnological methods to address a common health issue.
- Healthcare – The focus is on developing a novel treatment for obstructive sleep apnea, a prevalent healthcare condition that significantly affects global health, positioning the company within the healthcare industry.
- Private Equity & Venture Capital – EQT Life Sciences, a venture capital entity, plays a pivotal role by leading the investment round, indicating a significant financial interest and activity in this sector.
Financials
- USD 80 Million – The amount raised in the Series A funding round led by EQT Life Sciences for Mosanna Therapeutics.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Mosanna Therapeutics | Target Company | Company | A clinical-stage biotech company pioneering a novel treatment for obstructive sleep apnea. |
| EQT Life Sciences | Lead Investor | Company | A venture capital firm leading the Series A funding round for Mosanna Therapeutics. |
| David Weber, Ph.D. | CEO | Person | Appointed as the CEO of Mosanna Therapeutics with over 30 years of biotech industry experience. |
| Pivotal bioVenture Partners | Co-Lead Investor | Company | Acting as a co-lead investor in the funding round for Mosanna Therapeutics. |
| Forbion | Co-Lead Investor | Company | Participating as a co-lead investor in the investment round. |
| Norwest | Co-Lead Investor | Company | Involved as a co-lead investor in the Series A funding. |
| Broadview Ventures | Investor | Company | Part of the investment consortium for Mosanna Therapeutics. |
| Forty51 Ventures | Investor | Company | A founding investor returning in this round of funding. |
| Supermoon Capital | Investor | Company | Acts as a returning investor in this funding initiative. |
| High-Tech Grnderfonds (HTGF) | Investor | Company | Participated as an investor in the funding round. |
| Daniela Begolo, Ph.D. | Managing Director | Person | Managing Director at EQT Life Sciences, joining the Board of Directors at Mosanna. |